Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 76

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 76
---
2023, compared to $nil in the prior year. This expense was related to the RTO transaction and includes the cost to acquire Interactive and the costs incurred by RBx related to the transaction.

Summary of quarterly results

The following table sets forth selected unaudited quarterly results of operations data for each of the four quarters immediately preceding September 30, 2024. The information for each of these quarters has been derived from the condensed interim consolidated financial statements of the Company. Financial data for the four quarters including and immediately preceding the RTO, which occurred on September 29, 2023, have been omitted. Prior to the RTO, the Company existing as a shell company with no operations and its results of operations during this period are not relevant to its ongoing business.

<div align='center'>- 49 -</div>

|                                        |     | September 30, 
 2024          |   |     | June 30,   
 2024       |   |     | March 31,  
 2024       |   |     | December 31, 
 2023         |   |
|:---------------------------------------|:----|:--------------|:--|:----|:-----------|:--|:----|:-----------|:--|:----|:-------------|:--|
|                                        |     | $             |   |     | $          |   |     | $          |   |     | $            |   |
| Net loss                               |     | (2,959,216    | ) |     | (4,130,198 | ) |     | (1,791,521 | ) |     | (2,542,208   | ) |
| Net loss attributable to shareholders: |     |               |   |     |            |   |     |            |   |     |              |   |
| Basic and diluted                      |     | (0.31         | ) |     | (0.51      | ) |     | (0.22      | ) |     | (0.44        | ) |

Liquidity, Capital Resources and Financing

The general objectives of our capital management strategy are to preserve our capacity to continue operating, provide benefits to our stakeholders and provide an adequate return on investment to our shareholders by continuing to invest in our future in a manner that is commensurate with the level of operating risk we assume. We determine the total amount of capital required consistent with risk levels. This capital structure is adjusted